# A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

> **NCT00437502** · PHASE1 · COMPLETED · sponsor: **Michael Morse, MD** · enrollment: 8 (actual)

## Conditions studied

- Epithelial Ovarian, Tubal or Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** tumor peptide vaccine
- **BIOLOGICAL:** tumor peptide vaccine

## Key facts

- **NCT ID:** NCT00437502
- **Lead sponsor:** Michael Morse, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2012-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437502, "A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00437502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*